Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MC4R | P32245 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6113102 | 0.88 | KDM4E (0.47) | BRD4KDM4EALDH1A1HPGD | |
| SCHEMBL22560166 | 0.86 | BRD4 (0.38) | BRD4 | |
| SCHEMBL30753441 | 0.86 | BRD4 (0.38) | BRD4 | |
| SCHEMBL6112857 | 0.85 | NOTUM (0.38) | BRD4 | |
| SCHEMBL6112784 | 0.85 | DHFR (0.38) | KDM4E | |
| SCHEMBL1771400 | 0.85 | TUBB4A (0.43) | — | |
| SCHEMBL6112836 | 0.85 | BRD4 (0.38) | BRD4 | |
| SCHEMBL21715430 | 0.82 | PDE1A (0.38) | BRD4 | |
| SCHEMBL21715439 | 0.81 | MAPK1 (0.45) | KDM4EHPGD | |
| SCHEMBL6113057 | 0.81 | CYP1A2 (0.43) | MEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10807932-B2 | Benzosuberene analogues and related compounds with activity as anticancer agents | BAYLOR UNIVERSITY (US) | 2020-10-20 | — | — | US | disclosed |
| US-10807932-B2 | Benzosuberene analogues and related compounds with activity as anticancer agents | BAYLOR UNIVERSITY (US) | 2020-10-20 | — | — | US | disclosed |
| US-20200055805-A1 | BENZOSUBERENE ANALOGUES AND RELATED COMPOUNDS WITH ACTIVITY AS ANTICANCER AGENTS | BAYLOR UNIVERSITY (US) | 2020-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200055805-A1 | BENZOSUBERENE ANALOGUES AND RELATED COMPOUNDS WITH ACTIVITY AS ANTICANCER AGENTS | TUBB1, TUBB3, TUBB | BRD4 32/4885KDM4E 3545/4885ALDH1A1 2239/4885 |
| US-10807932-B2 | Benzosuberene analogues and related compounds with activity as anticancer agents | TUBB1, TUBB3, TUBB | BRD4 32/4885KDM4E 3545/4885ALDH1A1 2239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.